Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Study Summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

Conditions

Non-Small-Cell Lung Carcinoma NSCLC

Interventions / Drugs

MEDI4736 (Durvalumab)MEDI4736 (Durvalumab)+Tremelimumab Paclitaxel + Carboplatin Gemcitabine + Cisplatin Gemcitabine + Carboplatin Pemetrexed + Cisplatin Pemetrexed + Carboplatin Tremelimumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1118 participants

Primary Completion—

Lead SponsorAstraZeneca

Data Retrieved2026-04-11 02:55:19.909638+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.